MarketPeel
Insider Trading Intelligence
Pricing
…
KM

Keith S. Manchester

ROIV
DIRECTOR · ROIVANT SCIENCES LTD. · CIK 0001244828
FILING MIX · LIFETIME25%/75%
BUYS
14
SELLS
41
TOTAL VALUE
$258.68M
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
13,735,235
AVG SELL PX
$15.05
TRADE KIND
SHOWING 55 / 55
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Keith S. Manchester, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+28.57%+0.74%+0.28%+0.46%+1.85%—
14d7+85.71%-0.60%+1.73%-2.32%-2.73%—
30d7+0.00%+23.46%+0.70%+22.76%+35.49%—
60d7+0.00%+49.34%+1.68%+47.66%+83.13%—
90d7+14.29%+28.16%+5.50%+22.66%+43.93%—
180d7+42.86%+42.67%+4.92%+37.76%+75.89%—
1y7+14.29%+46.39%+15.13%+31.26%+56.68%—
2y7(3 pending)+0.00%+129.15%+56.03%+73.12%+73.12%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ROIV · 13,689,166 shares · as of Jun 30, 2026
09,645,57919,291,15728,936,73638,582,3142023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 14 buys / 41 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ROIV
ROIVANT SCIENCES LTD.
SALE
200,000$35.45$7.09M1,748,403Jun 30, 2026Jun 30, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
12,380$35.28$436.8K13,689,166Jun 30, 2026Jun 30, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
200,000$34.44$6.89M14,301,546Jun 29, 2026Jun 30, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
600,000$34.59$20.75M13,701,546Jun 29, 2026Jun 30, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
325,000$34.07$11.07M14,501,546Jun 26, 2026Jun 30, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
300,783$33.92$10.20M14,826,546Jun 26, 2026Jun 30, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
150,784$26.49$3.99M15,352,329Feb 13, 2026Feb 13, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
225,000$26.50$5.96M15,127,329Feb 13, 2026Feb 13, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
275,000$26.76$7.36M15,503,113Feb 12, 2026Feb 13, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
150,000$26.72$4.01M15,778,113Feb 12, 2026Feb 13, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
425,000$26.67$11.33M15,928,113Feb 11, 2026Feb 13, 2026 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
155,076$23.02$3.57M16,542,651Dec 17, 2025Dec 18, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
189,538$23.17$4.39M16,353,113Dec 17, 2025Dec 18, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
432,718$23.05$9.97M16,697,727Dec 17, 2025Dec 18, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
642,282$23.08$14.82M17,130,445Dec 16, 2025Dec 18, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
275,000$22.93$6.31M17,772,727Dec 16, 2025Dec 18, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
150,000$20.20$3.03M18,347,727Nov 19, 2025Nov 21, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
850,000$20.25$17.21M18,497,727Nov 19, 2025Nov 21, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
125,000$20.16$2.52M18,222,727Nov 19, 2025Nov 21, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
175,000$20.24$3.54M18,047,727Nov 19, 2025Nov 21, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
33,726——33,726Sep 10, 2025Sep 12, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
14,524——1,948,403Sep 10, 2025Sep 12, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
6,837,266——0Jun 25, 2025Jun 27, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
3,176,245——19,347,727Jun 25, 2025Jun 27, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
6,205,368——8,441,428Jun 25, 2025Jun 27, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
1,170,646——1,592,480Jun 25, 2025Jun 27, 2025 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
134,948$11.77$1.59M1,277,178Sep 25, 2024Sep 26, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
368,052$11.63$4.28M1,412,126Sep 24, 2024Sep 26, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
16,406——1,780,178Sep 10, 2024Sep 12, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
27,894——27,894Sep 10, 2024Sep 12, 2024 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASE
54,915$0.56$30.8K54,915Aug 14, 2024Aug 16, 2024 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE
54,915——0Aug 14, 2024Aug 16, 2024 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE
8,846$3.69$32.6K46,069Aug 14, 2024Aug 16, 2024 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
67,000——67,000May 23, 2024May 24, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
5,594,064——6,837,266Mar 7, 2024Mar 7, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
2,260,661——2,763,126Mar 7, 2024Mar 7, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
11,077,765——14,646,796Mar 7, 2024Mar 7, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
11,325,233——23,105,358Mar 7, 2024Mar 7, 2024 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
3,059,368$11.55$35.34M34,430,591Sep 28, 2023Oct 2, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
1,104,599$11.55$12.76M12,431,330Sep 28, 2023Oct 2, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
446,394$11.55$5.16M5,023,787Sep 28, 2023Oct 2, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
2,285,783$11.55$26.40M25,724,561Sep 28, 2023Oct 2, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
26,595——26,595Sep 12, 2023Sep 14, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
17,825——69,967Sep 12, 2023Sep 14, 2023 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
55,000——55,000May 24, 2023May 26, 2023 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
146,079$4.75$693.9K5,470,181Nov 10, 2022Nov 14, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
1,092,355$4.75$5.19M37,489,959Nov 10, 2022Nov 14, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
372,427$4.75$1.77M13,535,929Nov 10, 2022Nov 14, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
2,311,643$4.75$10.98M28,010,344Nov 10, 2022Nov 14, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
SALE
1,196,200——38,582,314Nov 9, 2022Nov 14, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
52,142——52,142Sep 15, 2022Sep 19, 2022 ↗View →
ROIV
ROIVANT SCIENCES LTD.
PURCHASEGRANT
Stock grant
71,850——71,850Sep 15, 2022Sep 19, 2022 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
41,000——41,000May 25, 2022May 26, 2022 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
22,000——22,000Jun 3, 2021Jun 7, 2021 ↗View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
22,000——22,000May 28, 2020Jun 1, 2020 ↗View →
Other insiders · ROIV
Loading peer insiders…
About this filer
CIK 0001244828
ROLE
Director
PRIMARY
ROIV
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001244828DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback